| A global analysis of the receptor tyrosine kinase-protein phosphatase interactome Z Yao, K Darowski, N St-Denis, V Wong, F Offensperger, A Villedieu, ... Molecular cell 65 (2), 347-360, 2017 | 142 | 2017 |
| Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC B Qiu, W Guo, F Zhang, F Lv, Y Ji, Y Peng, X Chen, H Bao, Y Xu, Y Shao, ... Nature communications 12 (1), 6770, 2021 | 136 | 2021 |
| PTP1B controls non-mitochondrial oxygen consumption by regulating RNF213 to promote tumour survival during hypoxia RS Banh, C Iorio, R Marcotte, Y Xu, D Cojocari, AA Rahman, J Pawling, ... Nature cell biology 18 (7), 803-813, 2016 | 114 | 2016 |
| Hepatic oxidative stress promotes insulin-STAT-5 signaling and obesity by inactivating protein tyrosine phosphatase N2 EN Gurzov, M Tran, MA Fernandez-Rojo, TL Merry, X Zhang, Y Xu, ... Cell metabolism 20 (1), 85-102, 2014 | 100 | 2014 |
| Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study Y Wang, L Yang, H Bao, X Fan, F Xia, J Wan, L Shen, Y Guan, H Bao, ... PLoS Medicine 18 (8), e1003741, 2021 | 76 | 2021 |
| Timing and origins of local and distant metastases in lung cancer WF Tang, M Wu, H Bao, Y Xu, JS Lin, Y Liang, Y Zhang, XP Chu, ZB Qiu, ... Journal of Thoracic Oncology 16 (7), 1136-1148, 2021 | 42 | 2021 |
| Complex ALK fusions are associated with better prognosis in advanced non-small cell lung cancer J Kang, XC Zhang, HJ Chen, WZ Zhong, Y Xu, J Su, Q Zhou, HY Tu, ... Frontiers in Oncology 10, 596937, 2020 | 32 | 2020 |
| Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation Y Jin, H Bao, X Le, X Fan, M Tang, X Shi, J Zhao, J Yan, Y Xu, K Quek, ... Oncogene 39 (9), 1846-1859, 2020 | 31 | 2020 |
| The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients Y Yang, T Zhang, J Wang, J Wang, Y Xu, X Zhao, Q Ou, Y Shao, X Wang, ... Molecular Cancer 21 (1), 117, 2022 | 21 | 2022 |
| Biochemical classification of disease-associated mutants of RAS-like protein expressed in many tissues (RIT1) Z Fang, CB Marshall, JC Yin, MT Mazhab-Jafari, GMC Gasmi-Seabrook, ... Journal of Biological Chemistry 291 (30), 15641-15652, 2016 | 21 | 2016 |
| Pathologic oxidation of PTPN12 underlies ABL1 phosphorylation in hereditary leiomyomatosis and renal cell carcinoma Y Xu, P Taylor, J Andrade, B Ueberheide, B Shuch, PM Glazer, RS Bindra, ... Cancer research 78 (23), 6539-6548, 2018 | 18 | 2018 |
| Integrated analysis of genomic and immunological features in lung adenocarcinoma with micropapillary component S Zhang, Y Xu, P Zhao, H Bao, X Wang, R Liu, R Xu, J Xiang, H Jiang, ... Frontiers in oncology 11, 652193, 2021 | 15 | 2021 |
| Prognostic value of circulating tumour DNA during post‐radiotherapy surveillance in locally advanced esophageal squamous cell carcinoma X Wang, N Yu, G Cheng, T Zhang, J Wang, L Deng, J Li, X Zhao, Y Xu, ... Clinical and translational medicine 12 (11), e1116, 2022 | 14 | 2022 |
| Quantitative characterization of tumor cell-free DNA shortening J Guo, K Ma, H Bao, X Ma, Y Xu, X Wu, YW Shao, M Jiang, J Huang BMC genomics 21, 1-11, 2020 | 14 | 2020 |
| Genomic profiling and prognostic value analysis of genetic alterations in Chinese resected lung cancer with invasive mucinous adenocarcinoma L Cai, J Wang, J Yan, J Zeng, L Zhu, J Liang, C Pan, X Huang, J Jin, Y Xu, ... Frontiers in Oncology 10, 603671, 2021 | 12 | 2021 |
| Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors Z Zhao, T Fu, J Gao, Y Xu, X Wu, W Chen, X Li, R Yu, YW Shao, M Li, ... Journal of medical genetics 58 (2), 79-86, 2021 | 11 | 2021 |
| Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer Y Yao, H Yang, B Zhu, S Wang, J Pang, X Wu, Y Xu, J Zhang, J Zhang, ... Respiratory Research 24 (1), 28, 2023 | 8 | 2023 |
| RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer C Wang, Z Zhang, Y Sun, S Wang, M Wu, Q Ou, Y Xu, Z Chen, Y Shao, ... Journal of Translational Medicine 20 (1), 390, 2022 | 8 | 2022 |
| Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing D Li, Y Huang, L Cai, M Wu, H Bao, Y Xu, Y Wei, S Wu, X Wu, Y Shao, ... Neoplasia 23 (12), 1204-1212, 2021 | 8 | 2021 |
| Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical … W Zhao, A Song, Y Xu, Q Wu, C Liu, JC Yin, Q Ou, X Wu, Y Shao, X Zhao BMC medicine 21 (1), 73, 2023 | 4 | 2023 |
